US2014295006A1PendingUtilityA1

Herbal composition for treating metastatic breast cancer

Assignee: LIN CHIH HUIPriority: Mar 28, 2013Filed: Mar 28, 2013Published: Oct 2, 2014
Est. expiryMar 28, 2033(~6.7 yrs left)· nominal 20-yr term from priority
Inventors:Chih-Hui Lin
A61K 2236/00A61K 36/076A61K 36/06A61K 36/51A61K 36/86A61K 36/236A61K 36/481A61K 36/36A61K 36/638A61K 36/484A61K 36/344A61K 36/748A61K 36/185A61K 36/288A61K 36/284
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a composition comprising a mixture of extracts obtained from Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla , and Viola philippica . The present invention further provides a method for treating metastatic breast cancer in a subject in need thereof, comprising: administering to said subject an pharmaceutically effective amount of the composition.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition comprising a mixture of extracts obtained from  Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla , and  Viola philippica.    
     
     
         2 . The composition of  claim 1 , wherein the extracts are organic solvent extracts. 
     
     
         3 . The composition of  claim 2 , wherein the organic solvent is selected from the group consisting of methanol, ethanol, acetic acid, ketone, hexane, propanol, isopropanol and chloroform. 
     
     
         4 . The composition of  claim 1 , wherein the extracts are obtained from the whole plants. 
     
     
         5 . The composition of  claim 1 , which has a concentration of ingredients as follows:
 250 mg/mL of  Atractylodes macrocephala,  330 mg/mL of  Astragalus membranaceus,  500 mg/mL of  Taraxacum mongolicum,  330 mg/mL of  Poria cocos,  250 mg/mL of  Ligusticum chuanxiong,  250 mg/mL of  Ligustrum lucidum,  250 mg/mL of  Codonopsis pilosula,  160 mg/mL of  Glycyrrhiza uralensis,  330 mg/mL of  Hedyotis diffusa,  250 mg/mL of  Pseudostellaria heterophylla , and 160 mg/mL of  Viola philippica.      
     
     
         6 . A method for treating metastatic breast cancer in a subject in need thereof, comprising: administering to said subject an pharmaceutically effective amount of a composition comprising a mixture of extracts obtained from  Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla , and  Viola philippica.    
     
     
         7 . The method of  claim 6 , wherein the extracts are organic solvent extracts. 
     
     
         8 . The method of  claim 7 , wherein the organic solvent is selected from the group consisting of methanol, ethanol, acetic acid, ketone, hexane, propanol, isopropanol and chloroform. 
     
     
         9 . The method of  claim 6 , wherein the extracts are obtained from the whole plants. 
     
     
         10 . The method of  claim 6 , which has a concentration of ingredients as follows:
 250 mg/mL of  Atractylodes macrocephala,  330 mg/mL of  Astragalus membranaceus,  500 mg/mL of  Taraxacum mongolicum,  330 mg/mL of  Poria cocos,  250 mg/mL of  Ligusticum chuanxiong,  250 mg/mL of  Ligustrum lucidum,  250 mg/mL of  Codonopsis pilosula,  160 mg/mL of  Glycyrrhiza uralensis,  330 mg/mL of  Hedyotis diffusa,  250 mg/mL of  Pseudostellaria heterophylla , and 160 mg/mL of  Viola philippica.      
     
     
         11 . The method of  claim 6 , wherein the metastatic breast cancer is refractory metastatic breast cancer. 
     
     
         12 . The method of  claim 6 , wherein the composition improves global health status/quality of life (GHS/QOL) scale of the subject. 
     
     
         13 . The method of  claim 6 , wherein the composition increases the level of CD3, CD4/CD8, CD19, and CD16+56 positive cells in the subject. 
     
     
         14 . The method of  claim 6 , wherein the composition increases the physical, role, emotional, and cognitive functioning. 
     
     
         15 . The method of  claim 6 , wherein the composition decreases fatigue and systemic therapy side effects.

Join the waitlist — get patent alerts

Track US2014295006A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.